Research and Markets (http://www.researchandmarkets.com/research/tg6kkv/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma-Pipeline Insights, 2015" subscription to their offering.

This Metastatic Renal Cell Carcinoma Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Renal Cell Carcinoma.

This report provides information on the therapeutic development based on the Metastatic Renal Cell Carcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  • Metastatic Renal Cell Carcinoma Overview
  • Metastatic Renal Cell Carcinoma Pipeline Therapeutics
  • Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies
  • Metastatic Renal Cell Carcinoma Late Stage Products (Filed and Phase III)
  • Comparative Analysis
  • Metastatic Renal Cell Carcinoma Mid Clinical Stage Products (Phase II)
  • Comparative Analysis
  • Metastatic Renal Cell Carcinoma Early Clinical Stage Products (Phase I and IND Filed)
  • Comparative Analysis
  • Metastatic Renal Cell Carcinoma Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Drug Candidate Profiles
  • Metastatic Renal Cell Carcinoma - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metastatic Renal Cell Carcinoma - Discontinued Products
  • Metastatic Renal Cell Carcinoma - Dormant Products
  • Companies Involved in Therapeutics Development for Metastatic Renal Cell Carcinoma
  • Appendix

For more information visit http://www.researchandmarkets.com/research/tg6kkv/metastatic_renal